Imaging of Slow Viruses

Neuroimaging Clinics of North America

Volumn 18, Issue 1, 2008, Pages 133-148

  Thurnher, Majda M ^a   Sundgren, Pia C ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NATALIZUMAB; PROTEINASE INHIBITOR;

CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC IMAGING; DISEASE COURSE; EPIDEMIC; EUROPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY; HUMAN; HYPOTHESIS; KURU; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; OBSERVATIONAL STUDY; PANENCEPHALITIS; PATHOGENESIS; PHYSICIAN; PRION; PRION DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROGRESSIVE RUBELLA PANENCEPHALITIS; RABIES; REVIEW; SCIENTIST; SCRAPIE AGENT; SLOW VIRUS DISEASE; SUBACUTE SCLEROSING PANENCEPHALITIS; UNITED KINGDOM; VETERINARY MEDICINE;

HUMANS; MAGNETIC RESONANCE IMAGING; NEURORADIOGRAPHY; PRION DISEASES; SLOW VIRUS DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 39749128429     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2007.12.014     Document Type: Review

References (99)

1. Berger J.R., and Concha M. Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J Neurovirol 1 (1995) 5-18
2. Thurnher M.M., Thurnher S.A., Mühlbauer B., et al. Progressive multifocal leukoencephalopathy in AIDS: initial and follow-up CT and MRI. Neuroradiology 39 (1997) 611-618
3. Von Einsiedel R.W., Fife T.D., Aksamit A.J., et al. Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature. J Neurol 240 (1993) 391-406
4. Kastrup O., Machke M., Diener H.C., et al. Progressive multifocal leukoencephalopathy limited to the brain stem. Neuroradiology 44 (2002) 227-229
5. Whiteman M.L.H., Post M.J.D., Berger J.R., et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 187 (1993) 233-240
6. Kotecha N., George M.J., Smith T.W., et al. Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status. Am J Med 105 (1998) 541-543
7. Port J.D., Miseljic S., Lee R.R., et al. Progressive multifocal leukoencephalopathy demonstrating contrast enhancement on MRI and uptake of thallium-201: a case report. Neuroradiology 41 (1999) 895-898
8. Wheeler A.L., Truwit C.L., Kleinschmidt-DeMasters B.K., et al. Progressive multifocal leukoencephalopathy: contrast enhancement on CT scans and MR imaging. AJR 161 (1993) 1049-1051
9. Woo H.H., Rezai A.R., Knopp E.A., et al. Contrast-enhancing progressive multifocal leukoencephalopathy: radiological and pathological correlations. Case report. Neurosurgery 39 (1996) 1031-1035
10. Ernst T.E., Chang L., Witt M.D., et al. Progressive multifocal leukoencephalopathy and human immunodeficiency virus-associated white matter lesions in AIDS: magnetization transfer MR imaging. Radiology 210 (1999) 539-543
11. Kuchelmeister K., Gullotta F., Bergmann M., et al. Progressive multifocal leukoencephalopathy (PML) in the acquired immunodeficiency syndrome (AIDS). A neuropathological autopsy study of 21 cases. Pathol Res Pract 189 (1993) 163-173
12. Chang L., Ernst T., Tornatore C., et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy: a proton magnetic resonance spectroscopy study. Neurology 48 (1997) 836-845
13. Iranzo A., Moreno A., Pujol J., et al. Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS. J Neurol Neurosurg Psychiatry 66 (1999) 520-523
14. Lee V.W., Antonacci V., Tilak S., et al. Intracranial mass lesions: sequential thallium and gallium scintigraphy in patients with AIDS. Radiology 211 (1999) 507-512
15. Berger J.R., Levy R.M., Flomenhoft D., et al. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44 (1998) 341-349
16. Post M.J.D., Yiannoutsos C., Simpson D., et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival?. AJNR Am J Neuroradiol 20 (1999) 1896-1906
17. Baqi M., Kucharczyk W., and Walmsley S.L. Regression of progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 11 (1997) 1526-1527
18. De Luca A., Giancola M.L., Cingolani A., et al. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 28 (1999) 624-628
19. Happe S., Besselmann M., Matheja P., et al. Therapy of progressive multifocal leukoencephalopathy (PML) in AIDS with Cidofovir (Vistide®). Review of the literature and two case reports. Nervenarzt 70 (1999) 935-943
20. Giudici B., Vaz B., Bossolasco S., et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30 (2000) 95-99
21. Mayo J., Collazos J., and Martinez E. Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy. AIDS 12 (1998) 1720-1722
22. Miralles P., Berenguer J., Garcia de Viedma D., et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 12 (1998) 2467-2472
23. Nicoli F., Chave B., Peragut J.C., et al. Efficacy of cytarabine in progressive multifocal leukoencephalopathy in AIDS. Lancet 339 (1991) 306
24. Portegies P., Algra P.R., Hollak C.E.M., et al. Response to cytarabine in progressive multifocal leukoencephalopathy in AIDS. Lancet 337 (1991) 680-681
25. Tassie J.M., Gasnault J., Bentata M., et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. AIDS 13 (1990) 1881-1887
26. Teofilo E., Gouveia J., Brotas V., et al. Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy. AIDS 12 (1998) 449
27. Cardenas R.L., Cheng K.H., and Sack K. The effects of cidofovir on progressive multifocal leukoencephalopathy: an MRI case study. Neuroradiology 43 (2001) 379-382
28. Shapiro R.A., Mullane K.M., Camras L., et al. Clinical and magnetic resonance imaging regression of progressive multifocal leukoencephalopathy in an AIDS patient after intensive antiretroviral therapy. J Neuroimaging 11 (2001) 336-339
29. Thurnher M.M., Donovan Post M.J., Rieger A., et al. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 22 (2001) 977-984
30. Collazos J., Mayo J., Martinez E., et al. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 13 (1999) 1426-1428
31. Miralles P., Berenguer J., Lacruz C., et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 15 (2001) 1900-1902
32. Tantisiriwat W., Tebas P., Clifford D.B., et al. Progressive multifocal leukoencephalopathy in AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28 (1999) 1152-1154
33. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1α for multiple sclerosis. N Engl J Med 353 (2005) 369-374
34. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
35. Greenlee J.E. Progressive multifocal leukoencephalopathy in the era of natalizumab: a review and discussion of the implications. Int MS J 13 (2006) 100-107
36. Biogen. TOUCH™ prescribingprogram. 2006. Available at: http://www.tysabri.com/touch.html. Accessed August 14, 2006.
37. Federal Drug and Trade Commission. Available at: http://www.fda.gov/cder/foi/appletter/2006/125104s015LTR.pdf. Accessed August 14, 2006.
38. Kappos L., Bates D., Hartung H.P., et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6 (2007) 431-441
39. Khalili K., White M.K., Lublin F., et al. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68 (2007) 985-990
40. Garg R.K. Subacute sclerosing panencephalitis. Postgrad Med J 78 (2002) 63-70
41. John T. Measles vaccination and risk of SSPE-reply. Indian Pediatr 36 3 (1999) 318
42. Prashanth L.K., Taly A.B., Ravi V., et al. Long term survival in subacute sclerosing panencephalitis: an enigma. Brain Dev 28 (2006) 447-452
43. Murata R., Matsuoka O., Nakajima S., et al. Serial magnetic resonance imaging in subacute sclerosing panencephalitis. Jpn J Psychiatry Neurol 41 (1987) 277-281
44. Ozturk A., Gurses C., Baykan B., et al. Subacute sclerosing panencephalitis: clinical and magnetic resonance imaging evaluation of 36 patients. J Child Neurol 17 (2002) 25-29
45. Brismar J., Gascon G.G., von Steyern K.V., et al. Subacute sclerosing panencephalitis: evaluation with CT and MR. AJNR Am J Neuroradiol 17 (1996) 761-772
46. Akdal G., Baklan B., Cakmakci H., et al. MRI follow-up of basal ganglia involvement in subacute sclerosing panencephalitis. Pediatr Neurol 24 (2001) 393-395
47. Senol U., Haspolat S., Cevikol C., et al. Subacute sclerosing panencephalitis: brain stem involvement in a peculiar pattern. Neuroradiology 42 (2000) 913-916
48. Lee K.Y., Cho W.H., Kim S.H., et al. Acute encephalitis associated with measles: MRI features. Neuroradiology 45 (2003) 100-106
49. Tekşam M., Çakir B., and Aǧildere A.M. Proton MR spectroscopy in the diagnosis of early stage subacute sclerosing panencephalitis. Diagn Interv Radiol 12 (2006) 61-63
50. Alkan A., Sarac K., Kutlu R., et al. Early- and late-state subacute sclerosing panencephalitis: chemical shift imaging and single-voxel MR spectroscopy. AJNR Am J Neuroradiol 24 (2003) 501-506
51. Yilmaz C., Caksen H., Yilmaz N., et al. Two cases of subacute sclerosing panencephalitis associated with brainstem involvement. J Trop Pediatr 53 4 (2007) 280-283
52. Trivedi R., Gupta R.K., Agarawal A., et al. Assessment of white matter damage in subacute sclerosing panencephalitis using quantitative diffusion tensor MR imaging. AJNR Am J Neuroradiol 27 (2006) 1712-1716
53. Kuroda Y., and Matsui M. Progressive rubella panencephalitis. Nippon Rinsho 55 (1997) 922-925
54. Merrer J., Perin-Dureau F., Appere C., et al. Severe forms of rubella encephalitis: arguments for a better vaccination policy. Presse Med 28 (1999) 395-397
55. Dupont J.R., and Earle K.M. Human rabies encephalitis: a study of forty-nine fatal cases with a review of the literature. Neurology 15 (1965) 23-34
56. Salomon T., Marston D., Mallewa M., et al. Paralytic rabies after a two week holiday in India. BMJ 331 (2005) 501-503
57. Mitrabhakdi E., Wannakrairot P., Shuangshoti S., et al. Difference in neuropathogenetic mechanisms in human furious and paralytic rabies. J Neurol Sci 238 (2004) 3-10
58. Mani J., Reddy B.C., Borgohain R., et al. Magnetic resonance imaging in rabies. Postgrad Med J 79 (2003) 352-354
59. Laothamatas J., Hemachudha T., Mitrabhakdi E., et al. MR imaging in human rabies. AJNR Am J Neuroradiol 24 (2003) 1102-1109
60. Pleasure S.J., and Fischbein N.J. Correlation of clinical and neuroimaging findings in a case of rabies encephalitis. Arch Neurol 57 (2000) 1765-1769
61. Awasthi M., Parmar H., Patankar T., et al. Imaging findings in rabies encephalitis. AJNR Am J Neuroradiol 22 (2001) 677-680
62. Jogai S., Radotra B.D., and Banerjee A.K. Immunohistochemical study of human rabies. Neuropathology 20 (2000) 193-203
63. Burton E.C., Burns D.K., Opatowsky M.J., et al. Rabies encephalomyelitis: clinical, neuroradiological and pathological findings in 4 transplant recipients. Arch Neurol 62 (2005) 873-882
64. Prusiner S.B. Prions. Proc Natl Acad Sci U S A 95 (1998) 13363-13383
65. Masters C.L., Harris J.O., Gajdusek D.C., et al. Creutzfeldt-Jacob disease; patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 5 (1979) 177-188
66. Kretzschmar H.A., Ironside J.W., DeArmond S.J., et al. Diagnostic criteria for sporadic Creutzfeldt-Jacob disease. Arch Neurol 53 (1996) 913-920
67. Zerr I., Poochiari M., Collins S., et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jacob disease. Neurology 55 (2000) 811-815
68. Aksamit Jr. A.J., Preissner C.M., and Hornburger H.A. Quantification of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jacob disease. Neurology 57 (2001) 728-730
69. Rosenburg C., Schulz-Schaeffer W.J., Meissner B., et al. Clinical course in young patients with sporadic Creutzfeldt-Jacob disease. Ann Neurol 58 (2005) 533-543
70. Meissner B., Köhler K., Körtner K., et al. Sporadic Creutzfeldt-Jacob disease magnetic resonance imaging and clinical findings. Neurology 63 (2004) 450-456
71. Cooper S.A., Murray K.L., Hearth C.A., et al. Sporadic Creutzfeldt-Jacob disease with cerebellar ataxia at onset in the UK. J Neurol Neurosurg Psychiatry 77 (2006) 1273-1275
72. Collins S., Boyd A., Fletcher A., et al. Recent advances in the pre-mortem diagnosis of Creutzfeldt-Jacob disease. J Clin Neurosci 7 (2000) 195-202
73. Parchi P., Giese A., Capellari S., et al. Classification of sporadic Creutzfeldt-Jacob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46 (1999) 224-233
74. Hill A.F., Joiner S., Wadsworth J.D., et al. Molecular classification of sporadic Creutzfeldt-Jacob disease. Brain 126 (2003) 1333-1346
75. Windl O., Dempster M., Estibeiro J.P., et al. Genetic basis of Creutzfeldt-Jacob disease in United Kingdom; a systematic analysis of predisposing mutations and allelic variations in the PRNP gene. Hum Genet 98 (1996) 259-264
76. Lundberg P.O. Creutzfeldt-Jacob disease in Sweden. J Neurol Neurosurg Psychiatry 65 (1998) 836-841
77. Brown P., Cathala F., Sadowsky D., et al. Creutzfeldt-Jacob disease in France: II. Clinical characteristics of 124 consecutive verified cases during the decade 1968-1977. Ann Neurol 6 (1979) 430-437
78. Poser S., Mollenhauer B., Kraus A., et al. How to improve the clinical diagnosis of Creutzfeldt-Jacob disease. Brain 112 (1999) 2345-2351
79. Collie D.A., Seller R.J., Zeidler M., et al. MRI of Creutzfeldt-Jacob disease: imaging features and recommended MRI protocol. Clin Radiol 56 (2001) 726-739
80. Parchi P., Petersen R.B., Chen S.G., et al. Molecular pathology of fatal familial insomnia. Brain Pathol 8 (1998) 539-548
81. Parchi P., Capeellari S., and Gambetti P. Intracerebral distribution of the abnormal isoform of the prion protein in sporadic Creutzfeldt-Jacob disease and fatal insomnia. Microsc Res tech 50 (2000) 16-25
82. Hamaguchi T., Kitamoto T., Sato T., et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jacob disease. Neurology 64 (2005) 643-648
83. Mastrianni J.A., Nixon R., Layzer R., et al. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med 340 (1999) 1630-1638
84. Hirsoe K., Iwasaki Y., Izumi M., et al. MM2-thalamic-type sporadic Creutzfeldt-Jacob disease with widespread neocortical pathology. Acta Neuropathol 112 (2006) 503-511
85. Waldman A.D., Cordery R.J., McManus D.G., et al. Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology 48 (2006) 428-433
86. Collinge J., Brown J., Hardy J., et al. Inherited prion disease with 144 base pair gene insertion: II: clinical and pathological features. Brain 115 (1992) 687-710
87. Tsuboi Y., Bab Y., Doh-ura K., et al. Diffusion-weighted MRI in familial Creutzfeldt-Jacob disease with the codon 200 mutation in the prion protein gene. J Neurol Sci 232 (2005) 45-49
88. de Priester J.A., Jansen G.H., de Kruijk J.R., et al. New MRI findings in Creutzfeldt-Jacob disease; high signal in the globus pallidus on T1-weighted images. Neuroradiology 41 (1999) 265-268
89. Fox N.C., Freeborough P.A., Mekkaoui K.F., et al. Cerebral and cerebellar atrophy on serial imaging in an initially symptom free subject at risk of familial prion disease. BMJ 315 (1997) 846-857
90. Zeidler M., Sellar R.J., Collie D.A., et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jacob disease. Lancet 355 (2000) 1412-1418
91. Bruhn H., weber T., Thorwirth V., et al. In-vivo monitoring of neuronal loss in Creutzfeldt-Jacob disease by proton magnetic resonance spectroscopy. Lancet 337 (1992) 1610-1611
92. Pandya H.G., Coley S.C., Wilkinson I.D., et al. Magnetic resonance spectroscopy abnormalities in sporadic and variant Creutzfeldt-Jacob disease. Clin Radiol 58 (2003) 148-153
93. Galanaud D., Dormont D., Grabli D., et al. MR spectroscopic pulvinar sign in a case of variant Creutzfeldt-Jacob disease. J Neuroradiol 29 (2002) 285-287
94. Cordery R, MacManus D, Rossor MN, et al. Short TE proton spectroscopy in variant and familial Creutzfeldt-Jacob disease. In: Proceedings ISMRM, presented at the 11th Scientific Meeting. 2003. p. 103.
95. Graham G.D., Pertroff O.A.C., Blamire A.M., et al. Proton magnetic resonance spectroscopy in Creutzfeldt-Jacob disease. Neurology 43 (1993) 2065-2068
96. Konaka K., Kaido M., Okuda Y., et al. Proton magnetic resonance spectroscopy of a patient with Gerstmann-Straussler-Scheinker disease. Neuroradiology 42 (2000) 662-665
97. Hadlow W.J. Neuropathology and the scrapie-kuru connection. Brain Pathol 5 (1995) 27-31
98. Poser C.M. Notes on the history of prion diseases. Clin Neurol Neurosurg 104 (2002) 77-86
99. De Pedro-Cuesta J., Glatzel M., Almazan J., et al. Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993-2002. BMC Public Health 6 (2006) 278